These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7619443)

  • 21. Trial of Edmonston-Zagreb measles vaccine in infants aged under nine months.
    Pongrithsukda V; Gluck R; Suwatanapongched S; Kaewmalung P; Muyakul J
    Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):347-50. PubMed ID: 1818384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine.
    Beck M; Smerdel S; Dedić I; Delimar N; Rajninger-Miholic M; Juzbasić M; Manhalter T; Vlatković R; Borcić B; Mihajić Z
    Dev Biol Stand; 1986; 65():95-100. PubMed ID: 3556780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age.
    Jensen TG; Whittle H; Mordhorst CH; Pedersen IR; Thaarup J; Poulsen A; Sodemann M; Jakobsen M; Brink L; Gansted U
    Vaccine; 1994 Aug; 12(11):1026-31. PubMed ID: 7975843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants.
    Tsai HY; Huang LM; Shih YT; Chen JM; Jiang TM; Tsai CH; Lee CY
    Viral Immunol; 1999; 12(4):343-8. PubMed ID: 10630793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lessons from measles vaccination in developing countries.
    Hall AJ; Cutts FT
    BMJ; 1993 Nov; 307(6915):1294-5. PubMed ID: 8257878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trial of high-dose Edmonston-Zagreb measles vaccine in the Gambia: antibody response and side-effects.
    Whittle H; Hanlon P; O'Neill K; Hanlon L; Marsh V; Jupp E; Aaby P
    Lancet; 1988 Oct; 2(8615):811-4. PubMed ID: 2902264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization of young infants with Edmonston-Zagreb measles vaccine.
    Markowitz LE; Bernier RH
    Pediatr Infect Dis J; 1987 Sep; 6(9):809-12. PubMed ID: 3313247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
    Wong-Chew RM; Islas-Romero R; García-García Mde L; Beeler JA; Audet S; Santos-Preciado JI; Gans H; Lew-Yasukawa L; Maldonado YA; Arvin AM; Valdespino-Gómez JL
    Vaccine; 2006 Jan; 24(5):683-90. PubMed ID: 16154241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced seroconversion to measles in infants given vitamin A with measles vaccination.
    Semba RD; Munasir Z; Beeler J; Akib A; Muhilal ; Audet S; Sommer A
    Lancet; 1995 May; 345(8961):1330-2. PubMed ID: 7752754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of high-titer Edmonston-Zagreb measles vaccine in human immunodeficiency virus-infected children in Kinshasa, Zaire.
    Cutts FT; Mandala K; St Louis M; Brown C; Mayala B; Zell ER; Deforest A; Kamenga M; Davachi F; Markowitz LE
    J Infect Dis; 1993 Jun; 167(6):1418-21. PubMed ID: 8501334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine.
    Whittle HC; Campbell H; Rahman S; Armstrong JR
    Lancet; 1990 Oct; 336(8722):1046-8. PubMed ID: 1977029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measles control in Kinshasa, Zaire improved with high coverage and use of medium titre Edmonston Zagreb vaccine at age 6 months.
    Cutts FT; Othepa O; Vernon AA; Nyandu B; Markowitz LE; Deforest A; Wilkins K; Okwo B
    Int J Epidemiol; 1994 Jun; 23(3):624-31. PubMed ID: 7960392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial.
    Dilraj A; Cutts FT; de Castro JF; Wheeler JG; Brown D; Roth C; Coovadia HM; Bennett JV
    Lancet; 2000 Mar; 355(9206):798-803. PubMed ID: 10711928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immuno-epidemiologic considerations on the prevention of measles in Mexico].
    Díaz-Ortega JL; Valdespino-Gómez JL; Zárate-Aquino ML; Camacho-Amor ML; González-Velázquez MS; Chávez-San Juan R
    Bol Med Hosp Infant Mex; 1990 Jul; 47(7):474-81. PubMed ID: 2206412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.
    Aaby P; Martins CL; Garly ML; Balé C; Andersen A; Rodrigues A; Ravn H; Lisse IM; Benn CS; Whittle HC
    BMJ; 2010 Nov; 341():c6495. PubMed ID: 21118875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants.
    Kiepiela P; Coovadia HM; Loening WE; Coward P; Botha G; Hugo J; Becker PJ
    Bull World Health Organ; 1991; 69(2):221-7. PubMed ID: 1860150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants.
    Hussey GD; Goddard EA; Hughes J; Ryon JJ; Kerran M; Carelse E; Strebel PM; Markowitz LE; Moodie J; Barron P; Latief Z; Sayed R; Beatty D; Griffin DE
    J Infect Dis; 1996 Jun; 173(6):1320-6. PubMed ID: 8648203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No evidence for short or long term morbidity after increased titer measles vaccination in Sudan.
    Libman MD; Ibrahim SA; Omer MI; Adlan IA; Bellavance F; Hoskins E; Bertley F; Ward B
    Pediatr Infect Dis J; 2002 Feb; 21(2):112-9. PubMed ID: 11840077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measles virus antibody responses in children randomly assigned to receive standard-titer edmonston-zagreb measles vaccine at 4.5 and 9 months of age, 9 months of age, or 9 and 18 months of age.
    Martins C; Garly ML; Bale C; Rodrigues A; Njie-Jobe J; Benn CS; Whittle H; Aaby P
    J Infect Dis; 2014 Sep; 210(5):693-700. PubMed ID: 24688075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term survival in trial of medium-titre Edmonston-Zagreb measles vaccine in Guinea-Bissau: five-year follow-up.
    Aaby P; Lisse IM; Whittle H; Knudsen K; Thaarup J; Poulsen A; Sodemann M; Jakobsen M; Brink L; Gansted U
    Epidemiol Infect; 1994 Apr; 112(2):413-20. PubMed ID: 8150016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.